Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by Gbathaton Apr 24, 2021 6:05pm
197 Views
Post# 33062237

When is antibody testing done and why is it important?

When is antibody testing done and why is it important?

https://www.mayoclinic.org/diseases-conditions/coronavirus/expert-answers/covid-antibody-tests/faq-20484429 

When is antibody testing done and why is it important?

Antibody testing, also known as serology testing, is usually done after full recovery from COVID-19. Eligibility may vary, depending on the availability of tests. A health care professional takes a blood sample, usually by a finger p*ick or by drawing blood from a vein in the arm. Then the sample is tested to determine whether you've developed antibodies against the virus. The immune system produces these antibodies — proteins that are critical for fighting and clearing out the virus.

If test results show that you have antibodies, it indicates that you were likely infected with COVID-19 at some time in the past. It may also mean that you have some immunity. But there's a lack of evidence on whether having antibodies means you're protected against reinfection with COVID-19. The level of immunity and how long immunity lasts are not yet known. Ongoing studies will eventually reveal more data on this.

The timing and type of antibody test affects accuracy. If you have testing too early in the course of infection, when the immune response is still building up in your body, the test may not detect antibodies. So antibody testing is not recommended until at least 14 days after the onset of symptoms. The U.S. Food and Drug Administration (FDA) authorized specific antibody tests, but tests with questionable accuracy are still on the market.

Another benefit of accurate antibody testing is that people who've recovered from COVID-19 may be eligible to donate plasma, a part of their blood. This plasma could be used to treat others with severe disease and boost the ability to fight the virus. Doctors call this convalescent plasma.

<< Previous
Bullboard Posts
Next >>